The Lancet
May 02, 2020 Volume 395 Number 10234 p1401-1460, e75-e82
https://www.thelancet.com/journals/lancet/issue/current

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial
Vianney Tricou,et al
An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in children living in dengue-endemic countries.